Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s crucial…


With biosim threats looming, Amgen hikes prices to fuel Q2 beats

J&J sets sights on bigger Darzalex market with FDA 'breakthrough' in second-line myeloma

Novartis CEO predicts drug pricing overhaul in U.S. after the election, whoever wins

FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught

Amgen, Daiichi Sankyo team up to sell biosimilars in Japan

In unanimous vote, FDA committee backs Amgen's Humira biosim

FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel

UPDATED: FDA gives Amgen approval for its once-monthly cholesterol device

Amgen picks up an edge for Repatha in duel with Sanofi and Regeneron

Amgen's Humira biosim 'highly similar' to AbbVie original, FDA staffers say